Enanta Pharmaceuticals Inc (ENTA NASDAQ) stock market data APIs
$6.2513
0.36(6.1%)
as of March 25, 2025
Enanta Pharmaceuticals Inc Financial Data Overview
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.
Prev. Close
5.894
Open
6.2513
High
6.188
Low
5.8579
52 wk Range
4.71-17.8
Market Cap
125 M
Shares Outstanding
21 333 K
Revenue
66 591 K
EPS
-1.05
Beta
0.481
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Enanta Pharmaceuticals Inc data using free add-ons & libraries
Get Enanta Pharmaceuticals Inc Fundamental Data
Enanta Pharmaceuticals Inc Fundamental data includes:
- Net Revenue: 66 591 K
- EBITDA: -107 765 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-02-05
- EPS/Forecast: -1.3525
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Enanta Pharmaceuticals Inc News
New
Enanta Pharmaceuticals, Inc. (ENTA): Caligan Partners’ Top Holding Right Now?
We recently compiled a list of the Top 10 Holdings of Caligan Partners.In this article, we are going to take a look at where Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) stands against Caligan Partners'...
Strength Seen in Enanta Pharmaceuticals (ENTA): Can Its 13.8% Jump Turn into More Strength?
Enanta Pharmaceuticals (ENTA) shares rallied 13.8% in the last trading session to close at $12.04. This move can be attributable to notable volume with a higher number of shares being traded than in a...
Enanta Pharmaceuticals to Provide Updates on its Research and Development Programs and 2024 Outlook at the 42nd Annual J.P. Morgan Healthcare Conference
Expansion into Immunology with New Discovery Program of Oral KIT Inhibitors Addressing High Unmet Need in Chronic Spontaneous Urticaria (CSU); Development Candidate Selection Targeted for 2024 Expect ...
Enanta Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
WATERTOWN, Mass., January 03, 2024--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs with an emphasis on ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
